Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMT2C siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
KMT2C siRNA is a small interfering RNA (siRNA) used as a research tool to induce transient knockdown of the KMT2C (Lysine Methyltransferase 2C) gene. KMT2C, also known as MLL3, encodes a histone methyltransferase that is part of the ASCOM complex and is involved in histone H3 lysine 4 (H3K4) methylation and transcriptional coactivation. In the context of endometrial cancer research, KMT2C siRNA has been utilized to demonstrate that KMT2C loss leads to reduced HER2 expression and increased expression of Arid1a and epithelial-to-mesenchymal transition (EMT) markers such as Snail and Slug. These findings suggest that KMT2C mutations may contribute to cancer pathogenesis and potentially reduce responsiveness to HER2-targeted therapies like trastuzumab.
- Other names
- KMT2C small interfering RNAKMT-2C small interfering RNAKMT 2C small interfering RNAMLL3 siRNAMLL-3 siRNAMLL 3 siRNA
02
Targets
Innate immune RNA sensorsKMT2C (KMT2C / MLL3)
Beyond the preview
Go deeper on KMT2C siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMT2C siRNA.